Rick E. Winningham - 01 Mar 2023 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role
CHIEF EXECUTIVE OFFICER, Director
Signature
/s/ Brett A Grimaud, Attorney-in-Fact
Issuer symbol
TBPH
Transactions as of
01 Mar 2023
Net transactions value
$0
Form type
4
Filing time
03 Mar 2023, 19:41:13 UTC
Previous filing
22 Feb 2023
Next filing
23 May 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction TBPH Ordinary Shares Award $0 +330,000 +25% $0.000000 1,643,377 01 Mar 2023 Direct F1
holding TBPH Ordinary Shares 92,567 01 Mar 2023 By Trust
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 1, 2023, the reporting person was granted 330,000 RSUs. 165,000 RSUs are subject to service-based vesting conditions and the remaining 165,000 RSUs vest based on the achievement of share price appreciation targets as well as continued employment.